EXHIBIT 99.1
                                                                    ------------


================================================================================

Paul A. Rosinack                                  Michael K. Green
President and CEO                                 Sr. Vice President and CFO
858-451-3771 x1401                                858-451-3771 x1407
paul@synbiotics.com                               mikeg@synbiotics.com
-------------------                               --------------------
================================================================================

                        SYNBIOTICS NAMES NEW MANAGEMENT

SAN DIEGO, CA., April 2, 2001... Synbiotics Corporation (Nasdaq:SBIO) announced
today that it has named Paul A. Rosinack President and CEO and a member of the
Board of Directors. Mr. Rosinack joined Synbiotics as Vice President and General
Manager in October 1996, when Synbiotics acquired the assets of International
Canine Genetics, of which he was President and CEO and a Director. He was
appointed President of Synbiotics' core animal health business in January of
2000. Kenneth M. Cohen, President and CEO and Director of Synbiotics since May
1996, resigned his position to pursue other opportunities. He will continue to
consult with the Company.

Synbiotics has also named Rigdon Currie to the position of Chairman of the Board
of Directors, replacing Donald Phillips, who will remain a Director.  Mr.
Currie, a Director of the Company since January 2000, is a private investor and
serves as a Director on the Boards of DISC, Inc., W3COMMERCE and other private
companies.

According to Mr. Currie, "Working closely with Don as Chairman, Ken Cohen has
led Synbiotics through three-fold growth and international expansion.  We thank
Ken for his tireless efforts on behalf of the Company and wish him future
success.  With our focus on the core business, Paul Rosinack, who directed the
Animal Health business through its restructuring in the second half of 2000, is
the ideal person to complete the successful turnaround of the Company."

Mr. Rosinack added, "While nearly tripling our diagnostic sales, we've built a
platform and assembled a team that can develop, manufacture and sell our broad
line of superb products throughout the world.  With the right financial or
strategic partner, we have an excellent opportunity to profitably grow our
business and I remain optimistic for a successful future."

Synbiotics Corporation is a leading developer, manufacturer and marketer of
veterinary diagnostics, instrumentation and related products.

With the exception of historical matters, the issues discussed in this press
release are forward-looking statements that are subject to the risks and
uncertainties that could cause actual results to differ materially from those
anticipated in the forward-looking statements, including the need for further
financing, the effects of uncertainty on our business while we explore strategic
alternatives for enhancing shareholder value, the possibility that Synbiotics
Animal Health could not be sold at a favorable price and terms, competition from
larger companies, reliance on third-party manufacturers and distributors,
possible technology improvements by others, the ability to assimilate acquired
businesses, the seasonality of major portions of the Company's business and
other risks set forth in Synbiotics Corporation's filings with the Securities
and Exchange Commission, particularly Form 10-K filed for the year ended
December 31, 2000.  These forward-looking statements represent Synbiotics
Corporation's judgment as of the date of the release.  Synbiotics Corporation
disclaims, however, any intent or obligation to update these forward-looking
statements.

                                     * * *